PPARγ activation blocks development and reduces established neuropathic pain in rats
J Morgenweck, RB Griggs, RR Donahue - Neuropharmacology, 2013 - Elsevier
Peroxisome proliferator-activated receptor gamma (PPARγ) is emerging as a new
pharmacotherapeutic target for chronic pain. When oral (3–30 mg/kg/day in chow for 7 wk) …
pharmacotherapeutic target for chronic pain. When oral (3–30 mg/kg/day in chow for 7 wk) …
PPARγ activation blocks development and reduces established neuropathic pain in rats
J Morgenweck, RB Griggs, RR Donahue… - …, 2013 - pubmed.ncbi.nlm.nih.gov
Peroxisome proliferator-activated receptor gamma (PPARγ) is emerging as a new
pharmacotherapeutic target for chronic pain. When oral (3-30 mg/kg/day in chow for 7 wk) or …
pharmacotherapeutic target for chronic pain. When oral (3-30 mg/kg/day in chow for 7 wk) or …
PPARγ activation blocks development and reduces established neuropathic pain in rats
J Morgenweck, RB Griggs, RR Donahue, JE Zadina… - …, 2013 - infona.pl
Peroxisome proliferator-activated receptor gamma (PPARγ) is emerging as a new
pharmacotherapeutic target for chronic pain. When oral (3–30 mg/kg/day in chow for 7 wk) …
pharmacotherapeutic target for chronic pain. When oral (3–30 mg/kg/day in chow for 7 wk) …
[HTML][HTML] PPARγ activation blocks development and reduces established neuropathic pain in rats
J Morgenweck, RB Griggs, RR Donahue… - …, 2013 - ncbi.nlm.nih.gov
Peroxisome proliferator-activated receptor gamma (PPARγ) is emerging as a new
pharmacotherapeutic target for chronic pain. When oral (3–30 mg/kg/day in chow for 7 wk) …
pharmacotherapeutic target for chronic pain. When oral (3–30 mg/kg/day in chow for 7 wk) …
PPARγ activation blocks development and reduces established neuropathic pain in rats
J Morgenweck, RB Griggs, RR Donahue… - …, 2013 - experts.umn.edu
Peroxisome proliferator-activated receptor gamma (PPARγ) is emerging as a new
pharmacotherapeutic target for chronic pain. When oral (3-30 mg/kg/day in chow for 7 wk) or …
pharmacotherapeutic target for chronic pain. When oral (3-30 mg/kg/day in chow for 7 wk) or …
PPARγ activation blocks development and reduces established neuropathic pain in rats.
J Morgenweck, RB Griggs, RR Donahue… - …, 2013 - europepmc.org
Peroxisome proliferator-activated receptor gamma (PPARγ) is emerging as a new
pharmacotherapeutic target for chronic pain. When oral (3–30 mg/kg/day in chow for 7 wk) …
pharmacotherapeutic target for chronic pain. When oral (3–30 mg/kg/day in chow for 7 wk) …
[引用][C] PPARγ activation blocks development and reduces established neuropathic pain in rats
J Morgenweck, RB Griggs, RR Donahue… - …, 2013 - cir.nii.ac.jp
PPARγ activation blocks development and reduces established neuropathic pain in rats | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
PPARγ activation blocks development and reduces established neuropathic pain in rats.
J Morgenweck, RB Griggs, RR Donahue… - …, 2013 - europepmc.org
Peroxisome proliferator-activated receptor gamma (PPARγ) is emerging as a new
pharmacotherapeutic target for chronic pain. When oral (3–30 mg/kg/day in chow for 7 wk) …
pharmacotherapeutic target for chronic pain. When oral (3–30 mg/kg/day in chow for 7 wk) …